Biosciences and TechnologiesMedical and Pharmacy

Dear EMBS friends and colleagues,
The IEEE Engineering in Medicine and Biology Society is pleased to announce the 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society, to be held in Bella Center, Copenhagen, Denmark, July 14-17, 2025.

The overarching conference theme, “Engineering Medicine, Innovating Healthcare”, underscores the pivotal role of interdisciplinary collaboration and new ways of working in driving transformative advancements in healthcare delivery and patient outcomes. Under this theme, we aim to drive the dynamic convergence of clinical practice, technology, and Artificial Intelligence with a focus on innovation,
entrepreneurship, and translation.

We will have a strong industry presence at the conference and explore entrepreneurial and translational aspects of biomedical engineering.
We will have a strong representation of women in engineering, recognizing their diverse and dynamic role in advancing innovation and positive transformations within the healthcare sector. We want to make the EMBC 2025 attractive for students and junior scientists by facilitating networking, science talks and career path discussions.

The conference will be the place to present your excellent research
and the scientific topics will span a wide spectrum, including but not limited to, medical imaging and diagnostics, wearables and ubiquitous computing, telemedicine, precision medicine, predictive analytics, robotic surgery and rehabilitation, and assistive technologies. By bringing together researchers, engineers, clinicians, and industry leaders, our conference will facilitate the exchange of ideas, insights, and best practices.

Attendees will have the opportunity to engage in interactive sessions, workshops, and demonstrations showcasing the latest breakthroughs in healthcare technology and AI applications. Together, we will delve into the possibilities of leveraging AI and cutting-edge technologies to address healthcare challenges, improve patient care, and enhance population health outcomes. Join us as we embark on a journey to revolutionize healthcare through innovation, AI, and technology integration.

The following Conference Program Themes should be considered for proposal submissions:
Biomedical Signal Processing
Biomedical Imaging Technology
Medical Image Computing
Tissue Engineering, Biomaterials and Nanotechnology
Systems, Computational and Synthetic Biology
Cardiopulmonary Systems and Physiology-based Engineering
Brain, Neural and Rehabilitation Engineering
Wearable Biomedical Sensors, Ubiquitous Computing, and Human-Machine Interfaces
Robotics, Biomechanics, Assistive and Augmentive Technologies
Therapeutic and Diagnostic Technologies
Biomedical and Health Informatics and Clinical Decision Support Systems
Emerging Technologies: Quantum in Life Science

Plenary Speakers:
Professor Dario Farina
Dario Farina is Full Professor and Chair in Neurorehabilitation Engineering at the Department of Bioengineering of Imperial College London, UK. At Imperial College, he is also Director of the Network of Excellence in Rehabilitation Technologies, and Director of the Imperial-Meta Wearable Neural Interfaces Research Centre. He has previously been Full Professor at Aalborg University, Aalborg, Denmark, (until 2010) and at the University Medical Center Göttingen, Georg-August University, Germany, where he founded and directed the Department of Neurorehabilitation Systems (2010-2016). Among other awards, he holds a Honorary Doctorate degree in Medicine from Aalborg University, Denmark, and has been the recipient of the IEEE Engineering in Medicine and Biology Society Early Career Achievement Award, the Royal Society Wolfson Research Merit Award, the IEEE EMBS Technical Achievement Award. His research focuses on biomedical signal processing, neurorehabilitation technology, and neural control of movement. Professor Farina has been the President of the International Society of Electrophysiology and Kinesiology (ISEK) (2012-2014) and is currently the Editor-in-Chief of the official Journal of this Society, the Journal of Electromyography and Kinesiology, and an Editor for many other international Journals, including Science Advances and IEEE Transactions on Biomedical Engineering. Professor Farina has been elected Fellow IEEE, AIMBE, ISEK, EAMBES, AAIA, Sigma Xi.

Katherine Ferrara
Dr. Ferrara is Professor of Radiology and Division Chief of the Molecular Imaging Program at Stanford University. She previously served as the founding chair of the Department of Biomedical Engineering at UC Davis. Dr. Ferrara is a member of the National Academy of Engineering and a fellow of the American Association for the Advancement of Science, Institute of Electrical and Electronic Engineers, Biomedical Engineering Society, Acoustical Society of America, World Molecular Imaging Society and American Institute of Medical and Biological Engineering. Her publications include more than 320 manuscripts at the intersection of molecular imaging and biology. Her laboratory has received awards that include the IEEE UFFC Achievement Award, the IEEE Ultrasonics Rayleigh Award, the IEEE Biomedical Engineering Award, the WMIC Gold Medal, the Distinguished Investigator Award from the Academy for Radiology and Biomedical Imaging Research, and the Judith Poole Award from the Association of Women in Science. Her contributions include work in ultrasound imaging and therapy and the use of positron emission tomography in therapeutic protocols.

Liselotte Højgaard
Professor Liselotte Højgaard, MD, DMSc, Liselotte Højgaard is a clinician scientist and specialist in Clinical Physiology & Nuclear Medicine. She was Head of Department of Rigshospitalet’s Department of Clinical Physiology, Nuclear Medicine & PET from 2000 to 2023, a leading clinical PET center in oncology. She is Professor at the University of Copenhagen in medical technology and Adjunct Professor at DTU. Højgaard is member of the Scientific Council of ERC and was previously President of EMRC The European Medical Research Councils, and Chair of the Danish National Research Foundation. She is member of the Board of Directors of the Novo Nordisk Foundation, The Bosch Foundation in Germany, and holds a Knighthood in Denmark and is Chevalier de la légion d’honneur in France. Her research with more than 250 peer review publications focuses on pathophysiology, nuclear medicine, and AI, and she has supervised more than 50 masters and Ph.D. students, the majority from bioengineering. She was co-founder of the cross disciplinary education as bioengineer in medicine and technology established in 2003 between DTU, The Technical University of Denmark, University of Copenhagen and Rigshospitalet.

Jeffrey Hubbell
Jeffrey Hubbell leads an initiative on translational biosciences and bioengineering as New York University’s Vice President of Strategy for Bioengineering. Before moving to New York University, Hubbell was at the University of Chicago in the Pritzker School of Molecular Engineering, where he helped build its strength in immunoengineering. Prior to that, he was on the faculty of the Swiss Federal Institute of Technology Lausanne (EPFL, where he served as founding Director of the Institute of Bioengineering and Dean of the School of Life Sciences), the Swiss Federal Institute of Technology Zurich (ETHZ) and University of Zurich, the California Institute of Technology, and the University of Texas in Austin. He was elected to the US National Academy of Engineering in 2010, the National Academy of Medicine in 2019, the American Academy of Arts and Sciences in 2021, and the National Academy of Sciences in 2023. With more than 400 papers and 100 issued US patents, Hubbell uses biomaterials and protein engineering approaches to investigate topics in regenerative medicine and immunotherapeutics. In regenerative medicine, he develops both materials and protein therapeutics to address issues such as chronic wound healing in diabetes and bone repair after trauma. In immunotherapeutics, he pursues nanomaterials in vaccination for infectious disease and cancer as well as targeted therapy with RNA, protein-material conjugates for inverse vaccines to induce antigen-specific tolerance in autoimmunity and allergy, and in protein therapy to tip immune balances toward aggression in immuno-oncology and toward tolerance in inflammatory disease. His interests are both basic and translational, having founded or co-founded six biomedical companies based on his technology.

Nicholas Peppas
Professor Nicholas A. Peppas is a biomedical/chemical engineer, materials scientist, and nanotechnologist whose research contributions, innovations, inventions have led to twenty chemical, medical and pharmaceutical products. Peppas is an elected member of the US-National Academy of Engineering, Academy of Medicine, American Academy of Arts and Sciences, Academy of Inventors, European Academy of Sciences, Academia Europaea, Canadian Engineering Academy, Indian National Engineering Academy, Chinese Academy of Engineering, Korean Academy of Science Technology, National Academy of France, Royal Academy of Spain, Academy of Athens, Greece, Academy of Romanian Scientists, Mexican Academy of Sciences, Academy of Texas, Royal Society of Chemistry (UK) and Italian Society for Medical and Biological Sciences. He has served as a Visiting Professor in the Universities of Geneva, Paris-Sud, Santiago de Compostela, Madrid, Lisbon, Parma, Pavia, Napoli, Hecettepe/Ankara, Athens, Berlin, Hebrew University/Jerusalem, Hoshi University/Tokyo, Nanyang University/Singapore, Sichuan University, Peking Medical College. Peppas is a distinguished professor in Chemical Engineering, Biomedical Engineering, Pediatrics, Surgery and Pharmacy, and a member of the Texas Materials Institute at the University of Texas at Austin. His group has set the fundamentals of flow and transport phenomena in numerous medical problems, based on the principles of engineering science and biology. He has numerous books, 1,850 publications and is cited in more than 225,000 references (H=215). Honored by 190 Awards including NAE Founders Award, NAM Adam Yarmolinsky, Pharmaceutical Global Leader Award, and the Biomaterials Global Impact Awards. Peppas holds a D.Eng. from NTU Athens, a ScD. from MIT and is the recipient of 16 honorary doctorates and professorships from France, Spain (2), Italy, Belgium, Greece (4), Slovenia, Romania, Israel and China (4). He is the Editor of Regenerative Biomaterials (Oxford) and Past-President on the International Sigma Xi organization.

Molly Stevens
Professor Dame Molly Stevens DBE FRS FREng is the John Black Professor of Bionanoscience at the University of Oxford and a part-time professor at Imperial College London and the Karolinska Institute. Molly’s multidisciplinary research balances the investigation of fundamental science with the development of technology to address some of the major healthcare challenges. She is a serial entrepreneur and the founder of several companies in the diagnostics, advanced therapeutics, and regenerative medicine fields. Her work has been instrumental in elucidating bio-material interfaces. She has created a broad portfolio of designer biomaterials for applications in disease diagnostics and regenerative medicine. Her substantial body of work influences research groups around the world and she has been multiple times listed as Clarivate Analytics Highly Cited Researcher in Cross-Field research. Molly holds numerous leadership positions, Deputy Director of the Kavli Institute for Nanoscience Discovery, Deputy Director of the UK Quantum Biomedical Sensing Research Hub, and Scientist Trustee of the National Gallery. She is a Fellow of the Royal Society and the Royal Academy of Engineering (UK), a Foreign Member of the National Academy of Engineering (USA), an International Honorary Member of the American Academy of Arts and Sciences, and she was recognised with the 2023 Novo Nordisk Prize and the 2024 Royal Society Armourers and Brasiers Company Prize, amongst many other accolades.

EMBC 2025 Conference Secretariat:
CAP Partner
Tel: +45 70200305
Email: info@cap-partner.eu